Barinthus Biotherapeutics (NASDAQ:BRNS) and Ayala Pharmaceuticals (NASDAQ:ADXS) Financial Comparison

Barinthus Biotherapeutics (NASDAQ:BRNS) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Profitability

This table compares Barinthus Biotherapeutics and Ayala Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-35.19%	-30.80%
Ayala Pharmaceuticals	N/A	-3,967.23%	-339.10%

Insider & Institutional Ownership

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 8.0% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Barinthus Biotherapeutics has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Barinthus Biotherapeutics and Ayala Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	0	0	2	0	3.00
Ayala Pharmaceuticals	0	1	0	0	2.00

Barinthus Biotherapeutics currently has a consensus target price of $8.00, indicating a potential upside of 252.42%. Given Barinthus Biotherapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Barinthus Biotherapeutics is more favorable than Ayala Pharmaceuticals.

Valuation and Earnings

This table compares Barinthus Biotherapeutics and Ayala Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$800,000.00	110.44	-$73.35 million	($1.92)	-1.18
Ayala Pharmaceuticals	$3.24 million	2.07	-$48.07 million	($7.98)	-0.08

Ayala Pharmaceuticals has higher revenue and earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Barinthus Biotherapeutics beats Ayala Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.